These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27731976)

  • 1. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
    Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Site-specific monoPEGylated interferon alpha2a mediated by microbial transglutaminase].
    Hui X; Cao W; Zhang D; Ge W; Li S; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):750-762. PubMed ID: 32347069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific derivatization of human interferon β-1a at lysine residues using microbial transglutaminase.
    Spolaore B; Forzato G; Fontana A
    Amino Acids; 2018 Jul; 50(7):923-932. PubMed ID: 29627904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-specific derivatization of avidin using microbial transglutaminase.
    Spolaore B; Damiano N; Raboni S; Fontana A
    Bioconjug Chem; 2014 Mar; 25(3):470-80. PubMed ID: 24517223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y; Zhai Y; Lei J; Ma G; Su Z
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
    Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
    J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
    Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
    J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].
    Pokholenko IaA; Porubleva LV; Dubeĭ IIa; Rebriev AV; Sutugina LP; Gromovoĭ TIu; Pokrovskiĭ VA; Obolenskaia MIu; Chernykh SI
    Ukr Biokhim Zh (1999); 2008; 80(6):92-100. PubMed ID: 19351063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local unfolding is required for the site-specific protein modification by transglutaminase.
    Spolaore B; Raboni S; Ramos Molina A; Satwekar A; Damiano N; Fontana A
    Biochemistry; 2012 Oct; 51(43):8679-89. PubMed ID: 23083324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
    Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
    Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
    Ramon J; Saez V; Baez R; Aldana R; Hardy E
    Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).
    Foser S; Schacher A; Weyer KA; Brugger D; Dietel E; Marti S; Schreitmüller T
    Protein Expr Purif; 2003 Jul; 30(1):78-87. PubMed ID: 12821324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-molecular crosslinking activity is engendered by the dimeric form of transglutaminase 2.
    Kim N; Lee WK; Lee SH; Jin KS; Kim KH; Lee Y; Song M; Kim SY
    Amino Acids; 2017 Mar; 49(3):461-471. PubMed ID: 27394142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase.
    Fontana A; Spolaore B; Mero A; Veronese FM
    Adv Drug Deliv Rev; 2008 Jan; 60(1):13-28. PubMed ID: 17916398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.
    Grace MJ; Cutler D
    Antivir Chem Chemother; 2004 Nov; 15(6):287-97. PubMed ID: 15646642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.